THE CURRENT STATUS AND FUTURE OF THERANOSTIC COPPER-64 RADIOPHARMACEUTICALS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

JALILIAN AMIR REZA; JOAO OSSO JR

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Nuclear Medicine Year:2017 | Volume:25 | Issue:1 (SERIAL NUMBER 47) Page(s): 1-10

Download Full-Text

View:

212

Download:

163

Cites:

Information Journal Paper

Title

THE CURRENT STATUS AND FUTURE OF THERANOSTIC COPPER-64 RADIOPHARMACEUTICALS

Author(s)

JALILIAN AMIR REZA | JOAO OSSO JR | Issue Writer Certificate

Keywords

COPPER-64

THERANOSTIC

RADIOPHARMACEUTICAL

CHELATES

PET

THERAPY

Abstract

COPPER-64 was produced in large scales and high specific activities in late 1990s’ using compact cyclotrons based by 64Ni (p, n) 64Cu reaction and many RADIOPHARMACEUTICALs developed since then by various groups based on interesting physicochemical and nuclear properties of the radionuclide. The unique emission of beta particles as well as positron particles offers a spectacular real therapeutic/diagnostic (“Theranostic ”) radionuclide in nuclear medicine. Although the development of COPPER-64 RADIOPHARMACEUTICALs continued with a slower rate in 2010s’ due to availability of 68Ga-tracers, however recent advances in application of therapeutic doses of 64Cu has emerged a new trend in the RADIOPHARMACEUTICAL development based on coppe-64. In this review, recent advances in the COPPER-64 THERANOSTIC RADIOPHARMACEUTICALs including introduction of new chelating groups with enhanced stability as well as radiolabelling conditions as well as application of simple 64CuCl2 RADIOPHARMACEUTICAL as areal THERANOSTIC agent in human subjects are summarized. A proposed strategy for development of peptide based COPPER-64 RADIOPHARMACEUTICALs with high and low dose therapeutic applications has been suggested.

Cites

No record.

References

No record.

Cite

APA: Copy

JALILIAN, AMIR REZA, & JOAO OSSO, JR. (2017). THE CURRENT STATUS AND FUTURE OF THERANOSTIC COPPER-64 RADIOPHARMACEUTICALS. IRANIAN JOURNAL OF NUCLEAR MEDICINE, 25(1 (SERIAL NUMBER 47)), 1-10. SID. https://sid.ir/paper/716413/en

Vancouver: Copy

JALILIAN AMIR REZA, JOAO OSSO JR. THE CURRENT STATUS AND FUTURE OF THERANOSTIC COPPER-64 RADIOPHARMACEUTICALS. IRANIAN JOURNAL OF NUCLEAR MEDICINE[Internet]. 2017;25(1 (SERIAL NUMBER 47)):1-10. Available from: https://sid.ir/paper/716413/en

IEEE: Copy

AMIR REZA JALILIAN, and JR JOAO OSSO, “THE CURRENT STATUS AND FUTURE OF THERANOSTIC COPPER-64 RADIOPHARMACEUTICALS,” IRANIAN JOURNAL OF NUCLEAR MEDICINE, vol. 25, no. 1 (SERIAL NUMBER 47), pp. 1–10, 2017, [Online]. Available: https://sid.ir/paper/716413/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops